Chromadex Corp reports results for the quarter ended in June - Earnings Summary

Niagen Bioscience

10/08/2022 22:03

* Chromadex Corp  CDXC.OQ  reported a quarterly adjusted
loss of 9
cents​​ per share for the quarter ended in June. The mean
expectation of six analysts for the quarter was for a loss of 8
cents per share.
    * Revenue fell 5.5% to $16.73 million from a year ago;
analysts
expected $18.65 million. 
    * Chromadex Corp's reported EPS for the quarter was a loss
of 9
cents​.
    * The mean earnings estimate of analysts had fallen by
about 18.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chromadex Corp shares had risen by 15.0% this quarter and
lost 48.7% so far this year.
    * The company reported a quarterly loss of $6.4 million.
    * Wall Street's median 12-month price target for Chromadex
Corp is
$7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.08          -0.09          Missed
 Mar. 31 2022      -0.09          -0.11          Missed
 Dec. 31 2021      -0.10          -0.08          Beat
 Sep. 30 2021      -0.09          -0.13          Missed